Articoli correlati a Drug Discovery in Cancer Epigenetics
Sinossi
Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.
- Highlights the potential of epigenetic alterations in cancer for drug development
- Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy
- Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
Informazioni sugli autori
Dr. Gerda Egger is an Associate Professor of Epigenetics at the Clinical Institute of Pathology, Medical University of Vienna.
Dr. Paola Barbara Arimondo is the Director of the Unité de Service et de Recherche (USR n°3388) entitled “Epigenetic Targeting of Cancer –ETaC-“ which brings together basic and applied research – a joint laboratory of the Institut de Recherche Pierre Fabre (IRPF) and the CNRS. She is extremely experienced in researching regulatory pharmaceuticals and cancer epigenetics.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
Compra nuovo
Visualizza questo articolo
EUR 110,38
EUR 11,00 per la spedizione da Italia a U.S.A.
Destinazione, tempi e costiRisultati della ricerca per Drug Discovery in Cancer Epigenetics
Foto dell'editore
Drug Discovery in Cancer Epigenetics
Print on DemandDa: Brook Bookstore On Demand, Napoli, NA, Italia
Valutazione del venditore 5 su 5 stelle
Condizione: new. Questo è un articolo print on demand. Codice articolo 8217d68e366f130cf6ec187fa1fb1b28
Quantità: Più di 20 disponibili
Foto dell'editore
Drug Discovery in Cancer Epigenetics (Translational Epigenetics Series)
Da: Chiron Media, Wallingford, Regno Unito
Valutazione del venditore 4 su 5 stelle
Hardcover. Condizione: New. Codice articolo 6666-ELS-9780128022085
Quantità: Più di 20 disponibili
Foto dell'editore
Drug Discovery in Cancer Epigenetics
Da: Revaluation Books, Exeter, Regno Unito
Valutazione del venditore 5 su 5 stelle
Hardcover. Condizione: Brand New. 1st edition. 498 pages. 9.50x8.00x1.00 inches. In Stock. Codice articolo __0128022086
Quantità: 2 disponibili
Foto dell'editore
Drug Discovery in Cancer Epigenetics
Editore:
Elsevier Science Publishing Co Inc, 2015
ISBN 10: 0128022086
ISBN 13: 9780128022085
Nuovo
Rilegato
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
Valutazione del venditore 5 su 5 stelle
Hardback. Condizione: New. New copy - Usually dispatched within 4 working days. 1200. Codice articolo B9780128022085
Quantità: Più di 20 disponibili
Immagini fornite dal venditore
Drug Discovery in Cancer Epigenetics
Print on DemandDa: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Valutazione del venditore 5 su 5 stelle
Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. 498 pp. Englisch. Codice articolo 9780128022085
Quantità: 2 disponibili
Immagini fornite dal venditore
Drug Discovery in Cancer Epigenetics
Da: moluna, Greven, Germania
Valutazione del venditore 5 su 5 stelle
Condizione: New. Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as bio. Codice articolo 151151580
Quantità: 1 disponibili
Immagini fornite dal venditore
Drug Discovery in Cancer Epigenetics
Print on DemandDa: AHA-BUCH GmbH, Einbeck, Germania
Valutazione del venditore 5 su 5 stelle
Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. Codice articolo 9780128022085
Quantità: 2 disponibili